Grifols SA GRFS
Grifols SA (Nasdaq: GRFS) is a hematology drug developer. Its lead program, Fibrinogen concentrate (BT524), is in Phase 3 for Congenital fibrinogen deficiency (US BLA approved 2025); acquired fibrinogen deficiency (EU approved, US Phase III to start 2026). Its next catalyst on record is Alpha-1 antitrypsin (SPARTA study): Grifols expects topline results from its Phase 3 SPARTA study evaluating Alpha-1 antitrypsin in patients with emphysema by the end of the fourth quarter of 2026. (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Alpha-1 antitrypsin (SPARTA study) — Grifols expects topline results from its Phase 3 SPARTA study evaluating Alpha-1 antitrypsin in patients with emphysema by the end of the fourth quarter of 2026. (Q4 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Fibrinogen BT524 | Congenital fibrinogen deficiency (US); congenital and acquired deficiency (EU) | biologic-other | Approved |
| Prolastin-C (alpha-1 proteinase inhibitor, IV) - SPARTA | Emphysema due to congenital alpha-1 antitrypsin deficiency | biologic-other | Approved |
| Xembify (subcutaneous immunoglobulin) | Secondary immunodeficiency in CLL, multiple myeloma and NHL | biologic-other | Phase 3 |
| Trimodulin | Severe community-acquired pneumonia (sCAP) | biologic-other | Phase 3 |
| Alpha-1 Proteinase Inhibitor SC 15% | Emphysema due to congenital alpha-1 deficiency (subcutaneous) | biologic-other | Phase 2 |
| Immunoglobulin eye drops (Flebogamma DIF 5%) | Dry eye disease | biologic-other | Phase 2 |
| ABvac40 (Araclon) | Early-stage Alzheimer's disease (active vaccine against A-beta40) | vaccine | Phase 2 |
| GIGA-2339 (GigaGen) | Hepatitis B virus infection | antibody | Phase 1 |
| GIGA-564 (GigaGen) | Advanced solid tumors | antibody | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 hematology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.